October 9, 2020
https://www.fdanews.com/articles/199454-kindredbio-partners-with-vaxart-for-covid-19-oral-vaccine
[-chart]www.kindredbio.com/wp-content/uploads/2020/02/burlingame-outside-1.jpg[/chart]
KindredBio has partnered with Vaxart to mass produce Vaxart’s oral capsule vaccine candidate for COVID-19, which would have an advantage over injected vaccines because of its simpler delivery method.
The agreement builds on an existing partnership between the two San Francisco-based companies. KindredBio subsidiary Centaur Biopharmaceutical Services will manufacture the vaccines at facilities in California and Kansas.
The new deal also includes other vaccines Vaxart is developing for norovirus, seasonal influenza, respiratory syncytial virus and human papillomavirus.
Recent KIN News
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
